Systemic Inflammatory Markers for Prediction of Bevacizumab Benefit in Glioblastoma Multiforme

Besiroglu, Mehmet; Shbair, Abdallah Tm; Yasin, Ayse Irem; Topcu, Atakan; Türk, Hacı Mehmet; Demir, Tarık

doi:10.29271/jcpsp.2021.01.39

Cited by 5 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some previous studies [ 34 – 38 ] have investigated the role of NLR, PLR, MLR, and AGR in GBM, but there was no consistent conclusion. In our study, we did not find the prognostic values of NLR, PLR, MLR, and AGR for the survival of GBM.…”

Section: Discussionmentioning

confidence: 92%

The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients

Nyalali

et al. 2022

Neurol Sci

View full text Add to dashboard Cite

Objectives The growth and development of tumors are closely related to the initiation and amplification of the inflammatory response. Various inflammatory biomarkers had attained growing attention for nearly two decades and were discovered strongly associated with cancer patients’ prognosis, indicating that systemic inflammatory response is possibly essential to cancer progression. However, little was known about the sensitive biomarkers associated with the detection, persistence, treatment, and prognosis of GBM. Hence, the retrospective research endeavored to evaluate the prognostic value of preoperative inflammatory biomarkers in patients with GBM who initially received standardized treatment. Methods The 232 glioblastoma patients eligible who were admitted to Qilu Hospitals in Shandong Province from January 2014 to January 2018 were collected for this analysis. Inflammatory markers, including the systemic immune-inflammation index (SII), systemic immune response index (SIRI), neutrophil–lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), and albumin/globulin ratio (AGR), were designed. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and we calculated the area under the ROC curve to determine the AUC value. Besides, we used the Cox proportional hazard model to estimate the relationship between variables and PFS and OS. The statistical differences between variables and PFS and OS were tested through the log-rank test. What is more, the LR method was used to perform Cox multiple regression analysis. The results were represented by hazard ratio (HR), 95% CI, any 2-tailed P < 0.01 was accepted as statistically different. Results The multivariate Cox proportional hazard model presented that SII ≥ 659.1 was an independent risk factor affecting OS (HR = 2.238, 95% CI = 1.471–3.406, P < 0.001) and postoperative PFS (HR = 2.000, 95% CI = 1.472–2.716, P < 0.001) in GBM patients. The 1-, 3-, and 5-year OS of the SII < 659.1 group was 70.8%, 26.9%, and 14.1%, respectively, while the 1- and 3-year OS of the SII ≥ 659.1 group was 37.5% and 11.5% ( P < 0.001). The 1-, 3-, and 5-year PFS of the SII < 659.1 group was 36.3%, 19.6%, and 13%, respectively, while the 1-year PFS of the SII ≥ 659.1 group was 11.3% ( P < 0.001). Results of patients’ clinical and pathological characteristics paraded that in comparison to the lower SII group, the higher SII group had significantly inferior Karnofsky Performance Scale (KPS) scores ( P < 0.001) and more frequent cystic changes of the tumors ( P < 0.001), whereas the values of SIRI, NLR, PLR, MLR, and AGR were low. Conclusions SII is an independent inflammatory indicator for predicting the prognosis of GBM pa...

show abstract

Section: Discussionmentioning

confidence: 92%

The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients

Nyalali

et al. 2022

Neurol Sci

View full text Add to dashboard Cite

show abstract

“…In the literature, SIII was investigated mostly in patients with malignancy. [22][23][24] Again, in studies conducted using psoriasis patients with intense inflammation, a significant increase was found in these patients compared to that in the control group. 25,26 Yorulmaz et al 26 have stated that SIII can be used as an independent prognostic indicator in patients with psoriasis and psoriatic arthritis.…”

Section: Discussionmentioning

confidence: 95%

The role of new inflammatory markers in determining disease activation and severity in patients with hidradenitis suppurativa

et al. 2023

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory disease. Recently published studies have suggested the use of markers of inflammation to monitor HS patients.These studies discuss the platelet/lymphocyte ratio (PLR), neutrophil/lymphocyte ratio (NLR), pan-immune-inflammation value (PIV), and systemic immune-inflammation index (SIII), which are also used in other inflammatory diseases. This study aimed to compare the blood parameters, including NLR, PLR, SIII, and PIV, in HS patients and healthy individuals, and determine their correlation with disease severity. The study included 81 HS patients and 61 healthy volunteers. The patients' medical records and laboratory values of the control group were reviewed retrospectively. HS severity was assessed using Hurley staging. NLR, PLR, SIII, and PIV values were calculated based on complete blood counts. NLR, SIII, and PIV values were significantly higher in HS patients compared to the healthy control group and were positively associated with disease severity. There was no significant difference observed in PLR values concerning disease severity. This study suggests that NLR, SIII, and PIV values can be utilized as simple and cost-effective tests to monitor disease activity and severity in HS patients. However, larger and more comprehensive studies are needed to establish diagnostic cutoff values, and further evaluation of sensitivity and specificity is required.

show abstract

“… Forest plot of NLR for subgroups [ 7 , 12 , 14 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 53 , 54 , 56 , 57 , 58 ]. …”

Section: Figurementioning

confidence: 99%

Prognostic Values of Systemic Inflammatory Immunological Markers in Glioblastoma: A Systematic Review and Meta-Analysis

Jarmużek

Kozłowska

Defort

et al. 2023

Cancers

View full text Add to dashboard Cite

Background. Neutrophils are an important part of the tumor microenvironment, which stimulates inflammatory processes through phagocytosis, degranulation, release of small DNA fragments (cell-free DNA), and presentation of antigens. Since neutrophils accumulate in peripheral blood in patients with advanced-stage cancer, a high neutrophil-to-lymphocyte ratio can be a biomarker of a poor prognosis in patients with glioblastoma. The present study aimed to explore the prognostic value of the preoperative levels of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune inflammation index (SII), systemic inflammation response index (SIRI), and cell-free DNA (cfDNA) to better predict prognostic implications in the survival rate of glioblastoma patients. Methods. The meta-analysis was carried out according to the recommendations and standards established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Databases of PubMed, EBSCO, and Medline were systematically searched to select all the relevant studies published up to December 2022. Results. Poorer prognoses were recorded in patients with a high NLR or PLR when compared with the patients with a low NLR or PLR (HR 1.51, 95% CI 1.24–1.83, p < 0.0001 and HR 1.34, 95% CI 1.10–1.63, p < 0.01, respectively). Similarly, a worse prognosis was reported for patients with a higher cfDNA (HR 2.35, 95% CI 1.27–4.36, p < 0.01). The SII and SIRI values were not related to glioblastoma survival (p = 0.0533 and p = 0.482, respectively). Conclusions. Thus, NLR, PLR, and cfDNA, unlike SII and SIRI, appeared to be useful and convenient peripheral inflammatory markers to assess the prognosis in glioblastoma.

show abstract

Systemic Inflammatory Markers for Prediction of Bevacizumab Benefit in Glioblastoma Multiforme

Abstract: Objective: To evaluate the predictive significance of systemic inflammation markers (SIMs) in patients with glioblastoma multiforme (GBM), who were treated with bevacizumab (Beva).

Cited by 5 publications

References 4 publications

The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients

The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients

The role of new inflammatory markers in determining disease activation and severity in patients with hidradenitis suppurativa

Prognostic Values of Systemic Inflammatory Immunological Markers in Glioblastoma: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About